Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
MedImmune, the biologics division of AstraZeneca, and Abpro, a synthetic biology specialist, are collaborating in a spin-off company, AbMed, that will develop antibodies targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). AbMed will operate as a subsidiary of Abpro, which will receive development and commercialization rights to research programs. MedImmune will receive development, regulatory, and sales milestone and royalty payments. MedImmune will also take a minority equity stake in AbMed.
This article has been sent to the following recipient: